Claims
- 1. A compound of the formula: ##STR32## wherein m is 0, 1 or 2 and n is 0 or 1, but m and n are never both 0;
- R.sup.1 is hydrogen or C.sub.1 -C.sub.6 -alkyl;
- R.sup.2 is C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one-to-three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino;
- R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; and
- R.sup.7 is hydrogen, methyl or ethyl;
- or a pharmaceutically-acceptable salt thereof.
- 2. A compound according to claim 1 wherein R.sup.1 is hydrogen, methyl or ethyl.
- 3. A compound according to claim 2 wherein m is 1, n is 0, R.sup.7 is hydrogen and R.sup.2 is C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino.
- 4. A compound according to claim 2 wherein m is 2, n is 0, R.sup.7 is hydrogen and R.sup.2 is C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino.
- 5. A compound selected from:
- 2-Methyl-1,2,3,4,4a,5,6,10b-octahydro-3-phenylmethyl-benz[f]isoquinoline;
- 8-Methoxy-2-methyl-1,2,3,4,4a,5,6,10b-octahydro-3-phenylmethyl-benz[f]isoquinoline;
- 2-Methyl-1,3,4,5,5a,6,7,11b-octahydro-3-phenylmethyl-2H-naphth[1,2-c]azepine; and
- 8-Methoxy-2-methyl-1,3,4,5,5a,6,7,11b-octahydro-3-phenylmethyl-2H-naphth[1,2-c]azepine hydrochloride, and
- (-)-cis-2-Methyl-1,3,4,5a,6,7,11b-octahydro-3-phenylmethyl-2H-naphth[1,2-c]azepine hydrochloride;
- or a pharmaceutically-acceptable salt thereof.
- 6. A pharmaceutical composition for treating affective disorders comprising a therapeutically-effective amount of a compound as defined in claim 1 and a pharmaceutically-acceptable carrier.
- 7. A pharmaceutical composition for treating affective disorders comprising a therapeutically-effective amount of a compound selected from the compounds named in claim 5 and a pharmaceutically-acceptable carrier.
- 8. A method of treating affective disorders comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound as defined in claim 1.
- 9. A method of treating affective disorders comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound selected from the compounds named in claim 5.
- 10. A method according to claim 8 wherein the affective disorder being treated is depression.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. application Ser. No. 07/672,011, filed Mar. 22, 1991, now U.S. Pat. No. 5,180,733, which is a continuation-in-part of U.S. application Ser. No. 07/570,234, filed Aug. 20, 1990, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07/502,601, filed Mar. 30, 1990, now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4348392 |
Fehr et al. |
Sep 1982 |
|
4666916 |
Schneider |
May 1987 |
|
4670443 |
Hartman et al. |
Jun 1987 |
|
5162335 |
Vanderwalle et al. |
Nov 1992 |
|
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
672011 |
Mar 1991 |
|
Parent |
570234 |
Aug 1990 |
|
Parent |
502601 |
Mar 1990 |
|